drugset / Trial / NCT04341454

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis

NCT04341454

Phase 3 Completed 327 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of study is to confirm the efficacy of DWP14012 X mg QD, DWP14012 Y mg BID compared to placebo in patients with Acute or Chronic Gastritis

Timeline

Start
2020-06-02
Primary completion
2021-08-04
Completion
2021-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule 10 mg Oral
Subject ABEPRAZAN Small molecule 20 mg Oral

Indications